If you register now, then you can choose to watch it live or later. The webinar will be available later, but without any CME points.

>LIVE:  25th July, 2026  Saturday 10:00 am (UK time zone)

Agenda

• 40 minutes presentation and then 20 minutes Q&A with the host Nathan Nagel
• Redefining obesity and cardiometabolic risk assessment beyond body mass index (BMI)
• Adipose tissue dysfunction, lipotoxicity, and ectopic fat as central drivers of cardiometabolic disease
• The role of ectopic fat deposition in MASLD/MASH, HFpEF, vascular disease, and beta-cell dysfunction
• Fibro-inflammation, extracellular matrix remodelling, and adipokine signalling in metabolic disease progression
• Clinical relevance of the “metabolically healthy obese” and “metabolically unhealthy lean” phenotypes
• Ethnic and regional cardiometabolic risk patterns, including the Asian diabetes phenotype
• Metabolic flexibility as a unifying concept in obesity and disease progression
• Translating mechanistic insights into patient classification, risk stratification, and precision medicine approaches
• Therapeutic implications of GLP-1 receptor agonists, tirzepatide, and emerging MASH therapies
• Future biomarkers and treatment targets derived from adipose tissue biology